BridgeMD
New treatment option for Dementia
Official title Early-Stage Partner in Care Living Alone Plus
ClinicalTrials.gov ID: NCT06962111
What this study is testing
- What it's testing
- EPICLA+ (Early-Stage Partners in Care Living Alone Plus) is a research project designed to assist people with early-stage memory loss who live alone in the community by providing early-stage related education and skill-training sessions, held via Zoom, designed to reduce stress, enhance well-being, manage challenges, and plan for the future. Researchers will gather feedback from individuals about their experience to continue to improve programs for early-stage memory loss.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 60 and older
You may be able to join if
- Early-stage 1. Must be at least 60 years of age
- Must be able to participate in English or Spanish
- Must be a US resident
- Must be able to provide consent verbally and in writing (electronically or via mail)
- Must exhibit at least 2 of 8 changes caused by thinking and memory problems on the AD8 (a reliable and valid 8-item dementia screening tool).
You likely can't join if
- Inability to participate via telephone or online video conferencing service.
- The participant expresses feelings of not wanting to participate
- The participant do not have enough time to attend the training,
- The participant demonstrates lack of skills with using a computer that precludes participation
- The participant does not have a stable internet connection to connect to the video platform
- The participant has difficulty hearing or a visual impairment that precludes participation.
See the full eligibility criteria
- Early-stage 1. Must be at least 60 years of age
- Must be able to participate in English or Spanish
- Must be a US resident
- Must be able to provide consent verbally and in writing (electronically or via mail)
- Must exhibit at least 2 of 8 changes caused by thinking and memory problems on the AD8 (a reliable and valid 8-item dementia screening tool).
- The Early-stage individual must have a diagnosis of early-stage ADRD or have a Mini-Mental State Exam (MMSE) score:
- between 20-26 for those who have completed high school, or
- between 17-26\ , for those who have not completed high school, or
- 27 or higher with a confirmed diagnosis of early-stage dementia or MCI.
- Able to participate in EPIC-LA workshops via zoom
- Inability to participate via telephone or online video conferencing service.
- The participant expresses feelings of not wanting to participate
- The participant do not have enough time to attend the training,
- The participant demonstrates lack of skills with using a computer that precludes participation
- The participant does not have a stable internet connection to connect to the video platform
- The participant has difficulty hearing or a visual impairment that precludes participation.
The study team makes the final eligibility decision.
Where it's taking place
- Phoenix, Arizona, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 60 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Phoenix, Arizona, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.